Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

SGMT

Sagimet Biosciences Inc

Apr 10 • 04:00PM ET

5.30

-0.34 -6.03 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX AMGN REGN GILD BIIB ILMN EXEL INCY NBIX BMRN

| Held by: VTI VXF IBB DFAS IWC AVSC DFMC DFAC DCOR DFSU

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.58	Insider Own	17.34%	Shs Outstand	31.95M	Perf Week	-0.38%
Market Cap	169.69M	Forward P/E	-	EPS next Y	-1.89	Insider Trans	-1.02%	Shs Float	26.93M	Perf Month	-7.67%
Enterprise Value	56.65M	PEG	-	EPS next Q	-0.37	Inst Own	37.42%	Short Float	11.98%	Perf Quarter	-4.85%
Income	-51.04M	P/S	-	EPS this Y	-5.12%	Inst Trans	-0.67%	Short Ratio	6.03	Perf Half Y	-27.50%
Sales	0.00M	P/B	1.55	EPS next Y	-13.76%	ROA	-36.89%	Short Interest	3.23M	Perf YTD	-10.47%
Book/sh	3.42	P/C	1.50	EPS next 5Y	-10.23%	ROE	-38.20%	52W High	11.41 -53.55%	Perf Year	137.67%
Cash/sh	3.53	P/FCF	-	EPS past 3/5Y	-3.41% -24.29%	ROIC	-45.82%	52W Low	2.02 162.38%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.00% 6.48%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-9.59%	Oper. Margin	-	ATR (14)	0.35	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	22.76	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	51.02	Recom	1.17
Dividend Gr. 3/5Y	- -	Current Ratio	22.76	EPS Q/Q	41.53%	SMA20	4.68%	Beta	3.18	Target Price	27.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-1.36%	Rel Volume	0.73	Prev Close	5.64
Employees	16	LT Debt/Eq	0.00	Earnings	Mar 11 BMO	SMA200	-23.70%	Avg Volume	534.99K	Price	5.30
IPO	Jul 14, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	32.90% -	Trades		Volume	392,384	Change	-6.03%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-26-26	Initiated	Rodman & Renshaw	Buy	$28
Feb-03-26	Initiated	Guggenheim	Buy	$27
Jan-28-26	Initiated	Barclays	Equal Weight	$8
Aug-11-25	Initiated	Wedbush	Outperform	$28
Aug-07-25	Resumed	H.C. Wainwright	Buy	$29
Jul-24-25	Initiated	Canaccord Genuity	Buy	$28
Dec-06-24	Initiated	Oppenheimer	Outperform	$30
Nov-12-24	Initiated	UBS	Buy	$12
Jun-28-24	Downgrade	Goldman	Buy → Neutral	$23 → $6
May-02-24	Initiated	H.C. Wainwright	Buy	$32
Mar-25-24	Initiated	Leerink Partners	Outperform	$26
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Piper Sandler	Overweight	$67
Aug-08-23	Initiated	JMP Securities	Mkt Outperform	$30
Aug-08-23	Initiated	Goldman	Buy	$33

Show Previous Ratings

Apr-06-26 07:00AM	Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-11-26 07:30AM	Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Mar-01-26 03:38PM	Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf. (MarketBeat)
Feb-25-26 07:00AM	Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences (GlobeNewswire)
Feb-15-26 03:06AM	Sagimet Biosciences Showcases FASN Strategy, MASH Phase II Timeline and Acne Data at Guggenheim Conference (MarketBeat)
07:00AM	Loading…
Feb-05-26 07:00AM	Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences (GlobeNewswire) -10.53%
Feb-03-26 03:27PM	After Clearing Up Acne, Sagimet Stock Rises (Barrons.com) +5.30%
09:34AM	Adobe downgraded, Palantir upgraded: Wall Street's top analyst calls (The Fly)
Feb-02-26 07:00AM	Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne (GlobeNewswire) +9.88%
Jan-08-26 07:00AM	Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference (GlobeNewswire)
Dec-18-25 07:00AM	Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination (GlobeNewswire)
Dec-17-25 07:00AM	Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet's Fixed Dose Combination Program (GlobeNewswire)
Dec-10-25 07:03AM	Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration (GlobeNewswire)
Dec-09-25 04:05PM	Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-20-25 07:00AM	Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference (GlobeNewswire) -7.39%
07:30AM	Loading…
Nov-13-25 07:30AM	Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) -12.24%
Nov-10-25 07:00AM	Sagimet Biosciences Presents Two Denifanstat Posters at AASLD-The Liver Meeting 2025 (GlobeNewswire) +10.77%
Oct-24-25 07:00AM	Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference (GlobeNewswire) +24.69%
Oct-15-25 12:00PM	All You Need to Know About Sagimet Biosciences Inc. (SGMT) Rating Upgrade to Strong Buy (Zacks)
Oct-14-25 07:00AM	Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences (GlobeNewswire)
Oct-07-25 07:00AM	Sagimet Biosciences Announces Upcoming Presentation at AASLD-The Liver Meeting 2025 (GlobeNewswire)
Oct-01-25 07:00AM	Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination (GlobeNewswire)
Sep-24-25 07:00AM	Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week (GlobeNewswire) +8.17%
Sep-17-25 07:00AM	Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis (GlobeNewswire)
Sep-16-25 09:35AM	Here's Why Sagimet Biosciences Inc. (SGMT) is Poised for a Turnaround After Losing 15.8% in 4 Weeks (Zacks)
Sep-10-25 07:00AM	Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit (GlobeNewswire)
Aug-26-25 07:00AM	Sagimet Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 12:00PM	Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:35AM	After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT) (Zacks)
Aug-13-25 07:30AM	Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
09:56AM	Loading…
Aug-07-25 09:56AM	Eli Lilly downgraded, Lyft upgraded: Wall Street's top analyst calls (The Fly)
Aug-05-25 07:00AM	Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire) +6.04%
Jun-11-25 12:00PM	What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now? (Zacks)
Jun-09-25 09:55AM	Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know (Zacks)
07:00AM	Sagimet Biosciences to Host Virtual KOL Event, "A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne" on June 16, 2025 (GlobeNewswire)
Jun-06-25 07:02AM	Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update (BioPharma Dive) +16.32%
Jun-04-25 08:28AM	Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps (Benzinga) +12.40%
05:00AM	Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis (GlobeNewswire)
May-22-25 08:00AM	Sagimet Biosciences to Host Virtual KOL Event, "Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)" on May 29, 2025 (GlobeNewswire) +5.90%
May-08-25 06:00AM	Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Apr-23-25 08:00AM	Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025 (GlobeNewswire) +8.82%
Mar-12-25 07:30AM	Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Mar-11-25 08:00AM	Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne (GlobeNewswire)
Feb-25-25 08:25AM	Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In? (Insider Monkey)
Feb-22-25 05:24PM	Sagimet Biosciences Inc. (SGMT): Among the Hot Penny Stocks to Buy Now (Insider Monkey)
Feb-19-25 08:00AM	Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium (GlobeNewswire)
Jan-06-25 08:00AM	Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference (GlobeNewswire) +36.42%
Dec-15-24 06:04AM	Oppenheimer Predicts Up to ~580% Jump for These 2 Strong Buy Stocks (TipRanks)
Nov-26-24 08:00AM	Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-18-24 08:00AM	Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting 2024 (GlobeNewswire) -7.82%
Nov-14-24 08:00AM	Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire) -13.95%
Nov-12-24 06:30AM	Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne (PR Newswire)
Nov-07-24 07:30AM	Sagimet Biosciences to Participate in the UBS Global Healthcare Conference (GlobeNewswire)
Oct-29-24 07:00AM	Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024 (GlobeNewswire)
Oct-16-24 07:00AM	Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting 2024 (GlobeNewswire) +6.43%
Oct-11-24 07:00AM	Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology (GlobeNewswire)
Oct-01-24 07:00AM	Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH (GlobeNewswire) +12.64%
12:05AM	Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-12-24 07:30AM	Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit (GlobeNewswire) -9.57%
Sep-04-24 08:00AM	Sagimet Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-14-24 08:00AM	Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire) -7.14%
Aug-01-24 08:00AM	Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors (GlobeNewswire)
Jun-10-24 08:00AM	Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat (GlobeNewswire)
Jun-06-24 05:00AM	Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024 (GlobeNewswire)
May-16-24 08:00AM	Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024 (GlobeNewswire)
May-15-24 12:53PM	SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q1 2024 (InvestorPlace) +5.48%
08:00AM	Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
May-07-24 08:00AM	Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024 (GlobeNewswire)
May-06-24 08:00AM	Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer (GlobeNewswire)
Apr-22-24 08:00AM	Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024 (GlobeNewswire)
Mar-27-24 04:01PM	Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat (GlobeNewswire) +9.56% -5.41%
Mar-25-24 07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire) +15.74%
06:15AM	Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Feb-29-24 08:00AM	Sagimet Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Jan-25-24 08:58PM	Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock (GlobeNewswire) -13.62% -23.89%
Jan-23-24 05:45PM	Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock (GlobeNewswire) -7.31%
Jan-22-24 11:10PM	Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH (PR Newswire) +170.09%
07:00AM	Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH (GlobeNewswire)
Dec-04-23 08:00AM	Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic (GlobeNewswire) +7.12%
Nov-28-23 08:00AM	Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit (GlobeNewswire)
Nov-22-23 08:00AM	Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +13.58%
Nov-13-23 08:00AM	Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire) -13.73%
Nov-10-23 08:30AM	Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting 2023 (GlobeNewswire) -7.68%
Oct-24-23 11:00AM	Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting 2023 (GlobeNewswire)
Oct-18-23 04:05PM	Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference (GlobeNewswire) -17.06%
Sep-27-23 04:05PM	Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma (GlobeNewswire)
Aug-29-23 10:21AM	Load Up, Says Goldman Sachs About These 2 Strong Buy Stocks (TipRanks)
Aug-21-23 04:02PM	Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire) -13.73%
Aug-15-23 04:04PM	Sagimet Biosciences Announces Closing of Underwriters Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering (GlobeNewswire) -7.71%
Aug-08-23 10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
Jul-20-23 04:05PM	Sagimet Biosciences Announces Leadership Changes (GlobeNewswire)
Jul-13-23 09:10PM	Sagimet Biosciences Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Happel David	President & CEO	Feb 10 '26	Sale	5.36	12,101	64,865	677,621	Feb 12 04:08 PM
Chauche Thierry	Chief Financial Officer	Feb 10 '26	Sale	5.36	1,312	7,033	15,688	Feb 12 04:07 PM
Martins Eduardo Bruno	Chief Medical Officer	Feb 10 '26	Sale	5.36	3,640	19,511	103,296	Feb 12 04:06 PM
Rozek Elizabeth	Chief Legal & Admin. Officer	Feb 10 '26	Sale	5.36	2,622	14,054	190,959	Feb 12 04:05 PM
Kemble George	Executive Chairman	Nov 20 '25	Sale	7.69	37,688	289,979	81,005	Nov 21 06:13 PM
GEORGE KEMBLE	Director	Nov 20 '25	Proposed Sale	7.85	37,688	295,851		Nov 20 04:21 PM
Happel David	President & CEO	Jul 21 '25	Sale	9.13	65,478	598,115	689,722	Jul 23 04:16 PM
Martins Eduardo Bruno	Chief Medical Officer	Jul 21 '25	Sale	9.13	8,277	75,607	106,936	Jul 23 04:15 PM
Rozek Elizabeth	General Counsel and CCO	Jul 21 '25	Sale	9.13	10,780	98,471	183,726	Jul 23 04:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SGMT

Sagimet Biosciences Inc

Upgrade your Finviz experience